Genentech, Inc.

F. Hoffmann-la Roche Ag

Tracy Staton

Mark S Dennis

Xiaocheng Chen

James T Koerber

Lawren Wu

Mason Lu

Janet K Jackman

Henry R Maun

Saroja Ramanujan

Tangsheng Yi

Kathila Rajapaksa

Michael Townsend

Alvernia Francesca Setiadi

Joseph R Arron

Rajita Khosla

Brian Yaspan

Amy Dressen

David Choy

Vladimir Ramirez-Carrozzi

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

Gene expression markers and treatment of multiple sclerosis

The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Anti-tryptase antibodies, compositions thereof, and uses thereof

The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the /L1RL1gene, the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the /L1RL1gene the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2.

Therapeutic and diagnostic methods for IL-33-mediated disorders

Growing community of inventors

Stanford, CA, United States of America

Tracy Staton